普萘洛尔治疗婴幼儿特殊部位血管瘤的临床研究  

Study on efficacy in the treatment of infantile privileged sites hemangioma with propranolol

作　　者：丁浩 杨荣强 

机构地区：[1]安徽省儿童医院普外一科,合肥230051

出　　处：《安徽卫生职业技术学院学报》2014年第6期37-38,共2页Journal of Anhui Health Vocational & Technical College

摘　　要：探讨普萘洛尔治疗婴幼儿特殊部位血管瘤的临床效果。方法：对某医院78例特殊部位（颜面部、会阴部、四肢关节处）血管瘤患儿给予口服普萘洛尔进行治疗。用药方案为：口服普萘洛尔起始量1.2mg/kg/d,同时监测患儿深度睡眠时的心率,如有异常,立即减量或停药随诊,无异常加量至1.5mg/kg/d后监测,出院后继续服药,治疗时间为半年,每月一次门诊随诊,及时观测患儿血管瘤质地、大小、颜色变化及不良反应,并用Achauer评分法对患儿的治疗效果进行评价。结果：评分为Ⅳ级（优）,瘤体缩小76%~100%,38例;Ⅲ级（好）,瘤体缩小51%~75%,31例;Ⅱ级（中）,瘤体缩小26%~50%,8例;I级（差）,瘤体缩小〈25%,1例。不良反应发生率3.85%,均为心率迟缓。结论：虽然必须进行大规模的随机对照试验进一步探讨口服普萘洛尔治疗血管瘤安全性,但对于治疗特殊部位血管瘤普萘洛尔可作为一线治疗或作为一个多通道的方法值得临床应用推广。To evaluate the efficacy of propranolol in treatment of privileged sites hemangioma. Methods： Oral propranolol was administered to 78 infants with privileged sites （face,perineum,the four limbs joint） hemangioma. They were treated with propranolol at 1.2 mg/kg/day, Parents monitoring children heart rate during deep sleep, If there are any abnormalities, immediately stop drug follow-up, No abnormal monitoring after added amount to 1.5 mg/kg/day. The patients were required a regular return visit once a month. The changes of tumor size, texture, color and adverse effects were monitored and recorded at a regular interval. The results were evaluated using Achauer system.Results： Among the 78 patients,the follow-up time was 6 months. Scale 1 was 1 patient,scale Ⅱ was 8 patient, scale Ⅲ was 31 patients, scale IV was 38 patients. No significant adverse reactions was observed and the overall adverse event incidence rate was3.85% .Conclusion： Although large-scale randomized controlled trials must be conducted in order to further evaluate the safety, but for the treatment of privileged site hemangioma propranolol may be as first-line therapy or as a muhichannel approach which is worth promoting in clinical application.

关 键 词：普萘洛尔 血管瘤 特殊部位 

分 类 号：R732.2[医药卫生—肿瘤]